Before taking on his new position as VP and general manager of GSK Greece, Antonino Biroccio was already familiar with the Greek affiliate, having spent three years there in previous roles before a five year global stint that took him to Spain and Singapore. Biroccio outlines the company's significant investments in Greece and the importance of the country as a hub for GSK’s clinical trial operations. He also discusses the need to introduce more value-based criteria for drug price negotiations in Greece in order to move away from a unique evaluation focus on price.
Greece is the second and third largest patient enroller globally for two of GSK’s clinical trials in lung cancer and multiple myeloma respectively, drawing on the high level of healthcare professionals that exist here
